Letters to the Editor
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases
Pathogenetic mechanism of macular edema during a treatment with ibrutinib: a case presentation.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: October 31, 2025
Accepted: December 3, 2025
Accepted: December 3, 2025
30
Views
214
Downloads
Authors
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are low-grade non-Hodgkin lymphomas characterized by monoclonal B lymphocytes. Bruton tyrosine kinase inhibitors represent the first-line treatment for symptomatic CLL/SLL. Here we report a case of a patient with SLL treated with ibrutinib who developed macular edema as confirmed by optical coherence tomography.
Downloads
Download data is not yet available.
Citations
Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol;32(1):23-33. DOI: doi.org/10.1016/j.annonc.2020.09.019
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New Engl J Med. 2013 Jul 4 ;369(1):32-42. DOI: doi.org/10.1056/nejmoa1215637
Mirgh SP, Ahmed R, Agrawal N, Bothra S, Mohan B, Garg A, Thekkudan SF, Khushoo V, Bhurani D. Knowing the Flip Side of the Coin: Ibrutinib Associated Cystoid Macular Edema. Indian J Hematol Blood Transfus. 2019 Sep 13; 36(1):208-10. DOI: doi.org/10.1007/s12288-019-01181-y
Saenz-de-Viteri M, Cudrnak T. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib. Leuk Amp Lymphoma. 2018 Sep 6; 60(3):842-4. DOI: doi.org/10.1080/10428194.2018.1508673
Bernard S, Goldwirt L, Amorim S, Brice P, Brière J, de Kerviler E, Mourah S, Sauvageon H, Thieblemont C. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015 Oct 1; 126(14):1695-8. DOI: doi.org/10.1182/blood-2015-05-647834
Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology. 2020 Dec 4 ;2020(1):336-45. DOI: doi.org/10.1182/hematology.2020000118
Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, Iwamoto Y, Wojtkiewicz G, Cetinbas M, Schloss MJ, Tedeschi J, Lebrun-Vignes B, Lundby A, Sadreyev RI, Moslehi J, Nahrendorf M, Ellinor PT, Milan DJ. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation. 2020 Dec 22;142(25):2443-55. DOI: doi.org/10.1161/circulationaha.120.049210
Fernandes AF, Bian Q, Jiang JK, Thomas CJ, Taylor A, Pereira P, Shang F. Proteasome Inactivation Promotes p38 Mitogen-activated Protein Kinase-dependent Phosphatidylinositol 3-kinase Activation and Increases Interleukin-8 Production in Retinal Pigment Epithelial Cells. Mol Biol Cell. 2009 Aug 15; 20(16):3690-9. DOI: doi.org/10.1091/mbc.e08-10-1068
Wu Y, Feng B, Chen S, Zuo Y, Chakrabarti S. Glucose-induced endothelin-1 expression is regulated by ERK5 in the endothelial cells and retina of diabetic ratsThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research. Can J Physiol Pharmacol. 2010 Jun;88(6):607-15. DOI: doi.org/10.1139/y10-033
Adasme MF, Parisi D, Van Belle K, Salentin S, Haupt VJ, Jennings GS, Heinrich JC, Herman J, Sprangers B, Louat T, Moreau Y, Schroeder M. Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor. PLOS ONE. 2020 May 27;15(5):e0233089. DOI: doi.org/10.1371/journal.pone.0233089
Zong Y, Miyagaki M, Yang M, Zhang J, Zou Y, Ohno-Matsui K, Kamoi K. Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies. Antibodies. 2024 Oct 11 ;13(4):86. DOI: doi.org/10.3390/antib13040086
Chavez-Solano M, Ibarra-Sanchez A, Treviño M, Gonzalez-Espinosa C, Lamas M. Fyn kinase genetic ablation causes structural abnormalities in mature retina and defective Müller cell function. Mol Cell Neurosci. 2016 Apr; 72:91-100. DOI: doi.org/10.1016/j.mcn.2016.01.008
How to Cite
“Pathogenetic mechanism of macular edema during a treatment with ibrutinib: a case presentation”. (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026009. doi:10.4084/MJHID.2026.009.
Copyright (c) 2026 Cristina Mauro, Livio Pupo, Lucia Cardillo, Fabiana Esposito, Elisa Buzzatti, Marco Lombardo, Massimo Cesareo, Adriano Venditti, Massimiliano Postorino, Maria Ilaria Del Principi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
